SG11202104637VA - MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPY - Google Patents
MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPYInfo
- Publication number
- SG11202104637VA SG11202104637VA SG11202104637VA SG11202104637VA SG11202104637VA SG 11202104637V A SG11202104637V A SG 11202104637VA SG 11202104637V A SG11202104637V A SG 11202104637VA SG 11202104637V A SG11202104637V A SG 11202104637VA SG 11202104637V A SG11202104637V A SG 11202104637VA
- Authority
- SG
- Singapore
- Prior art keywords
- mils
- therapy
- car
- chimeric antigen
- manufacturing same
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title 2
- 210000004698 lymphocyte Anatomy 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A61K39/4611—
-
- A61K39/4631—
-
- A61K39/464412—
-
- A61K39/464417—
-
- A61K39/464426—
-
- A61K39/464429—
-
- A61K39/464441—
-
- A61K39/464482—
-
- A61K39/464495—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Developmental Biology & Embryology (AREA)
- General Engineering & Computer Science (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862773384P | 2018-11-30 | 2018-11-30 | |
US201962828592P | 2019-04-03 | 2019-04-03 | |
US201962930886P | 2019-11-05 | 2019-11-05 | |
PCT/US2019/063605 WO2020113000A1 (en) | 2018-11-30 | 2019-11-27 | MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPY |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202104637VA true SG11202104637VA (en) | 2021-06-29 |
Family
ID=70853127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202104637VA SG11202104637VA (en) | 2018-11-30 | 2019-11-27 | MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPY |
Country Status (11)
Country | Link |
---|---|
US (2) | US20220257650A1 (en) |
EP (1) | EP3870191A4 (en) |
JP (1) | JP2022513687A (en) |
KR (1) | KR20210098485A (en) |
CN (1) | CN113396215A (en) |
AU (1) | AU2019387242A1 (en) |
CA (1) | CA3120323A1 (en) |
IL (1) | IL283073A (en) |
MX (1) | MX2021006399A (en) |
SG (1) | SG11202104637VA (en) |
WO (1) | WO2020113000A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107109364A (en) * | 2014-09-04 | 2017-08-29 | 约翰霍普金斯大学 | Anoxic and the activation of the bone marrow infiltration lymphocyte under normal oxygen alternation condition |
CN109735558B (en) * | 2018-12-12 | 2022-04-15 | 中南大学 | Recombinant CAR19-IL24 gene, lentiviral vector, CAR19-IL24-T cell and application |
WO2022066872A1 (en) * | 2020-09-24 | 2022-03-31 | Windmil Therapeutics, Inc. | Marrow infiltrating lymphocytes (mils) expressing t cell receptors, methods of manufacturing same, and method of using in therapy |
WO2022098982A1 (en) * | 2020-11-05 | 2022-05-12 | Windmil Therapeutics, Inc. | Breast cancer specific marrow infiltrating lymphocytes and uses thereof |
WO2022098977A1 (en) * | 2020-11-05 | 2022-05-12 | Windmil Therapeutics, Inc. | Head and neck cancer specific marrow infiltrating lymphocytes and uses thereof |
IL309674A (en) * | 2021-06-28 | 2024-02-01 | Meridian Therapeutics Inc | Compositions and methods of treating plasma cell disorders including multiple myeloma with a vaccine composition and myeloma-specific car-t cells |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107109364A (en) * | 2014-09-04 | 2017-08-29 | 约翰霍普金斯大学 | Anoxic and the activation of the bone marrow infiltration lymphocyte under normal oxygen alternation condition |
SI3230321T1 (en) * | 2014-12-12 | 2019-12-31 | Bluebird Bio, Inc. | Bcma chimeric antigen receptors |
WO2016172583A1 (en) * | 2015-04-23 | 2016-10-27 | Novartis Ag | Treatment of cancer using chimeric antigen receptor and protein kinase a blocker |
CN108137707A (en) * | 2015-06-29 | 2018-06-08 | 约翰霍普金斯大学 | Immunologic test point Chimerical receptor therapy |
MA42902A (en) * | 2015-07-08 | 2018-05-16 | Univ Johns Hopkins | MARINAL-INFILTRATING LYMPHOCYTES (MIL) AS A SOURCE OF T-LYMPHOCYTES FOR CHEMERIC ANTIGEN RECEPTOR (CAR) THERAPY |
WO2017190100A1 (en) * | 2016-04-28 | 2017-11-02 | The Trustees Of Dartmouth College | Nucleic acid constructs for co-expression of chimeric antigen receptor and transcription factor, cells containing and therapeutic use thereof |
CA3083118A1 (en) * | 2017-11-22 | 2019-05-31 | Iovance Biotherapeutics, Inc. | Expansion of peripheral blood lymphocytes (pbls) from peripheral blood |
AU2019240420A1 (en) * | 2018-03-22 | 2020-06-25 | Windmil Therapeutics, Inc. | Prostate cancer specific marrow infiltrating lymphocytes and uses thereof |
-
2019
- 2019-11-27 SG SG11202104637VA patent/SG11202104637VA/en unknown
- 2019-11-27 WO PCT/US2019/063605 patent/WO2020113000A1/en unknown
- 2019-11-27 MX MX2021006399A patent/MX2021006399A/en unknown
- 2019-11-27 CA CA3120323A patent/CA3120323A1/en active Pending
- 2019-11-27 JP JP2021531119A patent/JP2022513687A/en active Pending
- 2019-11-27 KR KR1020217019693A patent/KR20210098485A/en unknown
- 2019-11-27 AU AU2019387242A patent/AU2019387242A1/en not_active Abandoned
- 2019-11-27 EP EP19890764.4A patent/EP3870191A4/en active Pending
- 2019-11-27 US US17/297,333 patent/US20220257650A1/en not_active Abandoned
- 2019-11-27 CN CN201980078933.3A patent/CN113396215A/en active Pending
-
2021
- 2021-02-01 US US17/164,334 patent/US20210154233A1/en not_active Abandoned
- 2021-05-10 IL IL283073A patent/IL283073A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3870191A4 (en) | 2022-09-28 |
US20210154233A1 (en) | 2021-05-27 |
CA3120323A1 (en) | 2020-06-04 |
US20220257650A1 (en) | 2022-08-18 |
MX2021006399A (en) | 2021-07-15 |
AU2019387242A1 (en) | 2021-06-03 |
KR20210098485A (en) | 2021-08-10 |
EP3870191A1 (en) | 2021-09-01 |
WO2020113000A1 (en) | 2020-06-04 |
IL283073A (en) | 2021-06-30 |
CN113396215A (en) | 2021-09-14 |
JP2022513687A (en) | 2022-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL283073A (en) | Marrow infiltrating lymphocytes (mils) expressing chimeric antigen receptors (car), method of manufacturing same, and method of using in therapy | |
IL266230A (en) | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) | |
HK1251150A1 (en) | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) | |
ZA202208807B (en) | Anti-tigit antibodies and usage method | |
ZA201900792B (en) | Anti-pd-1 antibodies, method for producing same and method for using same | |
IL269656A (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment of cells that have an nrg1 fusion gene | |
IL283530A (en) | Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof | |
IL271179A (en) | Method of manufacturing bispecific antibodies, bispecific antibodies and therapeutic use of such antibodies | |
SG11202003782XA (en) | Triple-chain antibody, method for preparation and use thereof | |
MX2017017083A (en) | Marrow infiltrating lymphocytes (mils) as a source of t-cells for chimeric antigen receptor (car) therapy. | |
SG10201912494TA (en) | Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use | |
HK1248529A1 (en) | Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof | |
IL263627A (en) | Chimeric antigen receptors (cars) specific for muc1 and methods for their use | |
SG11202100308YA (en) | Bonding composition, conductor bonding structure, and method for producing same | |
GB202103876D0 (en) | Alumina sol-silane composite material, preparation method and application thereof | |
IL278862A (en) | Monospecific and multispecifc anti-tmeff2 antibodies and their uses | |
IL288607A (en) | High affinity anti-cd3 antibodies, and methods for their generation and use | |
PT3572156T (en) | Method for sorting luggage in an airport | |
ZA202003858B (en) | Monoclonal antibodies and methods for using same | |
IL310780A (en) | Anti-b7-h4/anti-4-1bb bispecific antibodies and use thereof | |
PL3643678T3 (en) | Sulfur-carbon composite and method for preparing same | |
EP3375875A4 (en) | SEPARATING AGENT FOR HUMAN SERUM-DERIVED IgG POLYCLONAL ANTIBODIES, AND METHOD FOR SEPARATING HUMAN SERUM-DERIVED IgG POLYCLONAL ANTIBODIES USING SAME | |
EP4058363A4 (en) | Integrated pick, place, and forming apparatus and method for composite charges over complex geometries | |
IL289158A (en) | Anti-cd123 antibodies, anti-cd123 chimeric antigen receptors and anti-cd123 chimeric antigen receptors t cells | |
EP3572169A4 (en) | Copper porous body, copper porous composite member, method for producing copper porous body, and method for producing copper porous composite member |